{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-022871","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.592655+00:00","generated_at":"2026-05-22T07:49:51.993265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lantheus Q1 adj EPS $1.53 (-9.5% YoY); cuts FY25 adj EPS guidance to $6.60-$6.70 from $7.00-$7.20","bullets":["Q1 revenue $372.8M (+0.8% YoY); GAAP EPS $1.02 vs $1.87; adj EPS $1.53 vs $1.69.","PYLARIFY sales $257.7M (-0.5%); DEFINITY $79.2M (+3.5%).","FY2025 revenue guidance narrowed to $1.550B-$1.585B; adj EPS guidance lowered to $6.60-$6.70 from $7.00-$7.20.","Closed Evergreen Theragnostics; agreed to acquire Life Molecular Imaging (Q2); announced SPECT divestiture to SHINE (by year-end).","MK-6240 met endpoints in pivotal studies; NDA planned Q3 2025. PNT2002 will not proceed to NDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-022871","json":"https://secwatch.observer/filing/0001628280-25-022871.json","markdown":"https://secwatch.observer/filing/0001628280-25-022871.md","text":"https://secwatch.observer/filing/0001628280-25-022871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000162828025022871/0001628280-25-022871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000162828025022871/lnth-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:49:51.993265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}